Achieve Life Sciences Joins Russell 2000® Index

Rhea-AI Summary

Achieve Life Sciences (Nasdaq: ACHV), a late-stage specialty pharmaceutical company developing cytisinicline for nicotine dependence, has been added to the Russell 2000 Index, effective June 26, 2026, as part of the Russell U.S. Indexes reconstitution. Achieve is also a member of the Russell 3000 Index, widely used by institutional investors and index-tracking funds.

News Market Reaction – ACHV

+3.49%

3 alerts

+3.49% Session close to close

$647.78M Market Cap

0.1x Rel. Volume

In the Jun 29 session, ACHV gained 3.49%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds ACHV to the Russell 2000®, exposing it to investors benchmarking $12.2 trilli...

Analysis

This announcement adds ACHV to the Russell 2000®, exposing it to investors benchmarking $12.2 trillion. Recent financings and a sizable resale shelf mean capital access is strong, but potential selling overhang remains a key factor to monitor.

Key Figures

Assets benchmarked: $12.2 trillion Russell 2000 constituents: approximately 2,000 small-cap U.S. equities Russell 3000 constituents: approximately 3,000 U.S. stocks +5 more

8 metrics

Assets benchmarked $12.2 trillion Assets benchmarked to Russell U.S. Indexes as of June 30, 2025

Russell 2000 constituents approximately 2,000 small-cap U.S. equities Constituent count for Russell 2000® Index

Russell 3000 constituents approximately 3,000 U.S. stocks Constituent count for Russell 3000® Index

U.S. equity coverage approximately 98% Portion of investable U.S. equities covered by Russell 3000® by market cap

Authorized common increase 150,000,000 to 300,000,000 shares Proposed charter amendment in 2026 proxy

Shares outstanding 102,659,057 shares Common shares outstanding as of May 15, 2026

Registered resale shares 99,037,138 shares Common stock registered for resale under S-3 shelf

Private placement size $354 million Private placement capacity announced with Q1 2026 results

Historical Context

5 past events · Latest: Jun 22 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 22	FDA CRL issued	Negative	+5.2%	FDA Complete Response Letter on cytisinicline NDA citing manufacturing and labeling issues.
Jun 02	Board appointments	Positive	-5.1%	Two new directors added as company prepares for NDA resubmission and launch.
May 19	Safety data update	Positive	-6.7%	52-week ORCA-OL trial showed no new safety signals for cytisinicline.
May 12	Leadership hires	Positive	+7.2%	Commercial and board leadership strengthened with executives from a successful past launch.
May 12	Earnings & financing	Positive	+7.2%	Q1 results plus large private placement and manufacturing partnership updates.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often shows divergence, with several positive clinical and corporate updates followed by negative price reactions.

Key Terms

russell 2000® index, russell 3000® index, russell u.s. indexes, market-capitalization rankings

4 terms

russell 2000® index financial

"it has been added to the Russell 2000® Index, effective June 26, 2026"

A stock market index that tracks the performance of roughly 2,000 publicly traded U.S. companies with smaller market values, representing the broader small-cap segment of the market. It matters to investors because it acts like a thermometer for smaller companies—used as a benchmark to compare fund performance, guide portfolio allocation, and gauge economic or market trends affecting growth-oriented, higher-risk firms.

russell 3000® index financial

"The Company is also a member of the Russell 3000® Index."

A broad stock market index that tracks the performance of about 3,000 publicly traded U.S. companies of all sizes, acting as a wide-ranging snapshot of the U.S. equity market. It matters to investors because it serves as a common yardstick for the overall market’s health and is the basis for many index funds and investment strategies—think of it as a single basket that shows how the whole U.S. stock market is doing.

russell u.s. indexes financial

"as part of the Russell U.S. Indexes reconstitution."

A family of U.S. stock market benchmarks that groups publicly traded companies by size and tracks their combined performance. Think of them as league tables that sort companies into tiers (large, mid, small) and measure how each tier is doing; investors use these indexes to compare fund performance, build passive funds or ETFs, and gauge which part of the market is strengthening or weakening.

market-capitalization rankings financial

"FTSE Russell determines membership ... by objective, market-capitalization rankings and style attributes."

Market-capitalization rankings are a list that orders companies by their market value — the share price multiplied by the number of shares outstanding — so the biggest firms appear at the top and smaller ones lower down. For investors this matters because size often signals stability, liquidity, index inclusion and how a company is compared to peers, much like ranking ships by tonnage to gauge their carrying capacity and reliability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that it has been added to the Russell 2000® Index, effective June 26, 2026, as part of the Russell U.S. Indexes reconstitution. The Company is also a member of the Russell 3000® Index.

Approximately $12.2 trillion in assets, as of June 30, 2025, are benchmarked against the Russell U.S. Indexes, making them one of the most widely used benchmarks for institutional investors, index-tracking funds, and active investment strategies. The Russell 2000® Index measures the performance of approximately 2,000 small-cap U.S. equities, and the Russell 3000® Index measures the performance of approximately 3,000 of the largest U.S. stocks, representing approximately 98% of investable U.S. equities by market capitalization. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

About Cytisinicline
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products.

About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding the timing, nature and outcome of cytisinicline clinical development and regulatory review and approval, data results, the timing, nature and success of Achieve’s commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, the performance of Achieve’s third-party manufacturing partners, the successful launch and commercialization of cytisinicline, and statements concerning Achieve Life Sciences’ future plans and prospects. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those described in Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Achieve Contact
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
425-686-1510

References
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM, doi: 10.1056/EVIDpha2500339.

FAQ

What did Achieve Life Sciences (ACHV) announce about the Russell 2000 Index on June 29, 2026?

Achieve Life Sciences announced its addition to the Russell 2000 Index, effective June 26, 2026. According to Achieve Life Sciences, this inclusion follows the annual reconstitution of the Russell U.S. Indexes, which are widely tracked by institutional investors and index funds.

When did Achieve Life Sciences (ACHV) become a member of the Russell 2000 Index?

Achieve Life Sciences became a member of the Russell 2000 Index effective June 26, 2026. According to Achieve Life Sciences, this change occurred as part of the annual reconstitution of the Russell U.S. Indexes, which determine membership based on market-capitalization rankings and style attributes.

Is Achieve Life Sciences (ACHV) also included in the Russell 3000 Index?

Yes, Achieve Life Sciences is also a member of the Russell 3000 Index. According to Achieve Life Sciences, the Russell 3000 Index tracks approximately 3,000 of the largest U.S. stocks and represents about 98% of investable U.S. equities by market capitalization.

What does inclusion in the Russell 2000 Index mean for Achieve Life Sciences (ACHV) investors?

Inclusion in the Russell 2000 Index can increase visibility among institutional investors and index funds. According to Achieve Life Sciences, about $12.2 trillion in assets were benchmarked to Russell U.S. Indexes as of June 30, 2025, highlighting their broad market use.

How are companies like Achieve Life Sciences (ACHV) selected for Russell U.S. Indexes?

Companies are selected for Russell U.S. Indexes primarily through objective market-capitalization rankings and style attributes. According to FTSE Russell, this rules-based approach determines membership for indexes such as the Russell 2000 and Russell 3000, which track small-cap and broad U.S. equities.